Toxicologie > Valeurs de référence > Autres valeurs des organismes reconnus
Last update the 06/07/2026| Target | Exposure route | Effect type | Exposure type | Value name | Value | Source | Commentary | Critical effect retained | Status state | Exposure duration | Environment | Exposure source | Factor | Management context | Age dependent adjustments factors | ADAF - Age range | ADAF - Value | ADAF - URL |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Population générale | Inhalation | A seuil | Chronique | RfC | 0,002 mg.m-3 | US EPA (1991) | Degeneration and inflammation of nasal respiratory epithelium hyperplasia of mucous secreting cells | Final | Air ambiant | |||||||||
| Population générale | Inhalation | A seuil | Chronique | REL | 5 µg.m-3 | OEHHA (2003) | Degeneration and inflammation of nasal epithelium in rats | Final | Air ambiant | |||||||||
| Population générale | Inhalation | Sans seuil | Chronique | Inhalation Unit Risk | 0,000068 (µg.m-3)-1 | US EPA (1987) | Respiratory cancer | Final | Air ambiant | |||||||||
| Population générale | Inhalation | Sans seuil | Chronique | Risque Unitaire | 0,0083 (mg.m-3)-1 | OMS CICAD (2002) | CT0,5= 6 mg/m3 | tumeur du cerveau et de la moelle épinière | Final | Air ambiant | ||||||||
| Population générale | Inhalation | Sans seuil | Chronique | Inhalation Unit Risk | 0,00029 (µg.m-3)-1 | OEHHA (1999) | Human respiratory tract cancer incidence data | Final | Air ambiant | |||||||||
| Population générale | Orale | Sans seuil | Chronique | Oral Slope Factor | 0,54 (mg.kg-1.j-1)-1 | US EPA (1987) | Brain and spinal cord astrocytomas, Zymbal gland carcinomas and stomach papillomas/ carcinomas | Final | Eau | |||||||||
| Population générale | Inhalation | A seuil | Sub-chronique | MRL | 0,0008 ppm | ATSDR (2025) | Hyperplasia of nasal respiratory/transitional zone epithelium | Final | Air ambiant | 30 | ||||||||
| Population générale | Orale | A seuil | Aiguë | MRL | 0,09 mg.kg-1.j-1 | ATSDR (2025) | Total fetal malformations | Final | 100 | |||||||||
| Population générale | Orale | A seuil | Chronique | MRL | 0,00009 mg.kg-1.j-1 | ATSDR (2025) | Increased severity of forestomach hyperplasia | Final | 1000 | |||||||||
| Population générale | Orale | A seuil | Sub-chronique | MRL | 0,02 mg.kg-1.j-1 | ATSDR (2025) | Forestomach hyperplasia | Final | 100 |